ONCONASE VS DOXORUBICIN IN MALIGNANT MESOTHELIOMA

阿霉素是治疗恶性间皮瘤的常用化疗药物。Onconase是一种实验性药物(未经FDA批准)，已显示出对恶性间皮瘤的活性。这项研究的目的是确定在恶性间皮瘤的治疗中，Onconase注入血流是否比注射阿霉素更好。全国约160名患者将参加这项研究。这些患者将接受Onconase每周超过30分钟的静脉滴注，或每3周接受一次阿霉素，最多6剂。治疗将持续至少18周，或者直到肿瘤对治疗不再有反应。在治疗停止后，医生将对患者进行监测，以确定晚期副作用和未来的治疗方法。

Doxorubicin is a commonly used chemotherapy agent in the treatment of malignant mesothelioma. Onconase is an experimental (not approved by the FDA) drug that has shown activity against malignant mesothelioma. The purpose of this study is to determine whether Onconase, when administered into the blood stream, is better than injection of Doxorubicin into the blood stream for the treatment of malignant mesothelioma. Approximately 160 patients across the country will be enrolled on this study. These patients will receive either Onconase by intravenous infusion over 30 minutes weekly, or Doxorubicin every 3 weeks for a maximum of 6 doses. Treatment will continue for at least 18 weeks or until the tumor is no longer responding to treatment. After treatment has been stopped, patients will be monitored by a physician to determine late side effects and future therapy.